Anti-inflammatory effects of pancreatitis associated protein in inflammatory bowel disease

Gut

Volumn 54, Issue 9, 2005, Pages 1244-1253

  Gironella, M ^a,b   Iovanna, J L ^b   Sans, M ^a   Gil, F ^a   Penalva M ^a   Closa, D ^c   Miquel, R ^a   Pique J M ^a   Panes J ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b INSERM   (France)

^c INST D INVESTIGACIONS B   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PANCREATITIS ASSOCIATED PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIUM CELL; ENTERITIS; EPITHELIUM CELL; FEMALE; GASTROINTESTINAL ENDOSCOPY; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE BIOPSY; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PANETH CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; ULCERATIVE COLITIS;

ANALYSIS OF VARIANCE; ANTIGENS, NEOPLASM; BIOLOGICAL TRANSPORT; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; CELL NUCLEUS; CELLS, CULTURED; COLITIS; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKINS; INTESTINAL MUCOSA; LECTINS, C-TYPE; NF-KAPPA B; PANETH CELLS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 23944474547     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.056309     Document Type: Article

References (42)

1. Keim V, Rohr G, Stockert HG, et al. An additional secretory protein in the rat pancreas. Digestion 1984;29:242-9.
2. Okamoto H. The Reg gene family and Reg proteins: with special attention to the regeneration of pancreatic beta-cells. J Hepatobiliary Pancreat Surg 1999;6:254-62.
3. Christa L, Carnot F, Simon MT, et al. HIP/PAP is an adhesive protein expressed in hepatocarcinoma, normal Paneth, and pancreatic cells. Am J Physiol 1996;271:G993-1002.
4. Dieckgraefe BK, Stenson WF, Korzenik JR, et al. Analysis of mucosal gene expression in inflammatory bowel disease by parallel oligonucleotide arrays. Physiol Genomics 2000;4:1-11.
5. Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum Mol Genet 2001;10:445-56.
6. Ogawa H, Fukushima K, Naito H, et al. Increased expression of HIP/PAP and regenerating gene III in human inflammatory bowel disease and a murine bacterial reconstitution model. Inflamm Bowel Dis 2003;9:162-70.
7. Shytenberg A, Kandil E, Lin Y, et al. Dp-regulation of pancreatitis-associated protein in a rat model of inflammatory bowel disease. J Surg Res 2003;114:292-3.
8. Fiedler F, Croissant N, Rehbein C, et al. Acute-phase response of the rat pancreas protects against further aggression with severe necrotizing pancreatitis. Crit Care Med 1998;26:887-94.
9. Zhang H, Kandil E, Lin YY, et al. Targeted inhibition of gene expression of pancreatitis-associated proteins exacerbates the severity of acute pancreatitis in rats. Scand J Gastroenterol 2004;39:870-81.
10. Heller A, Fiedler F, Schmeck J, et al. Pancreatitis-associated protein protects the lung from leukocyte-induced injury. Anesthesiology 1999;91:1408-14.
11. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's disease activity index (CDAI). Gastroenterology 1979;77:843-6.
12. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.
13. Hanauer SB, Robinson M, Pruitt R, et al. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. Gastroenterology 1998;115:525-32.
14. Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000;47:404-9.
15. D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998;114:262-7.
16. Keim V, Iovanna JL, Orelle B, et al. A novel exocrine protein associated with pancreas transplantation in humans. Gastroenterology 1992;103:248-54.
17. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993;94:174-81.
18. Mitsuyama K, Sasaki E, Toyonaga A, et al. Colonic mucosal interleukin-6 in inflammatory bowel disease. Digestion 1991;50:104-11.
19. Banks C, Bateman A, Payne R, et al. Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J Pathol 2003;199:28-35.
20. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996;157:1261-70.
21. Pallone F, Monteleone G. Interleukin 12 and Th1 responses in inflammatory bowel disease. Gut 1998;43:735-6.
22. Pizarro TT, Michie MH, Bentz M, et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol 1999;162:6829-35.
23. Collart MA, Baeuerle P, Vassalli P. Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B. Mol Cell Biol 1990;10:1498-506.
24. Dendorfer U, Oettgen P, Libermann TA. Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglanains, cyclic AMP, and lipopolysaccharide. Mol Cell Biol 1994; 14:4443-54.
25. Kunsch C, Lang RK, Rosen CA, et al. Synergistic transcriptional activation of the IL-8 gene by NF-kappa B p65 (RelA) and NF-IL-6. J Immunol 1994;153:153-64.
26. Murphy TL, Cleveland MG, Kulesza P, et al. Regulation of interleukin 12 p40 expression through an NF-kappa B half-site. Mol Cell Biol 1995;15:5258-67.
27. Suk K, Yeou KS, Kim H. Regulation of IL-18 production by IFN gamma and PGE2 in mouse microglial cells: involvement of NF-kB pathway in the regulatory processes. Immunol Lett 2001;77:79-85.
28. Tsuji-Takayama K, Aizawa Y, Okamoto I, et al. Interleukin-18 induces interferon-gamma production through NF-kappaB and NFAT activation in murine T helper type 1 cells. Cell Immunol 1999;196:41-50.
29. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-205.
30. Rogler G, Brand K, Vogl D, et al. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998;115:357-69.
31. Thiele K, Bierhaus A, Autschbach F, et al. Cell specific effects of glucocorticoid treatment on the NF-kappaBp65/IkappaBalpha system in patients with Crohn's disease. Gut 1999;45:693-704.
32. Binion DG, West GA, Ina K, et al. Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease. Gastroenterology 1997;112:1895-907.
33. Pooley N, Ghosh L, Sharon P. Dp-regulation of E-selectin and intercellular adhesion molecule-1 differs between Crohn's disease and ulcerative colitis. Dig Dis Sci 1995;40:219-25.
34. Collins T, Read MA, Neish AS, et al. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J 1995;9:899-909.
35. Desjeux A, Barthet M, Barthellemy S, et al. Serum measurements of pancreatitis associated protein in active Crohn's disease with ileal location. Gastroenterol Clin Biol 2002;26:23-8.
36. Panes J. Adhesion molecules: their role in physiopathology and treatment of inflammatory bowel disease. Gastroenterol Hepatol 1999;22:514-24.
37. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002;122:1592-608.
38. Feagan BG, McDonald JW, Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. N Engl J Med 1994;330:1846-51.
39. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000;342:1627-32.
40. Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996;110:1416-21.
41. Niessner M, Volk BA. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol 1995;101:428-35.
42. Autschbach F, Giese T, Gassler N, et al. Cytokine/chemokine messenger-RNA expression profiles in ulcerative colitis and Crohn's disease. Virchows Arch 2002;441:500-13.